Petrelintide for weight management in people with overweight or obesity and heart disease
Tests petrelintide against placebo in adults with overweight or obesity and cardiovascular disease.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Key facts
- Where
- Anniston, Los Angeles, and Port Orange, United StatesSee the 3 sites
- Phase
- Phase 3
Where in United States
- Pinnacle Research GroupAnniston, United StatesTaking people
- Institute for Metabolic Research Los AngelesLos Angeles, United StatesTaking people
- Progressive Medical ResearchPort Orange, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07843472EU 2026-526190-41-00
- Record updated
- 7 October 2026
- Original description
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Inclusion: Participants with BMI ≥ 27 kg/m² and established CVD; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Current or previous treatment with petrelintide or any other amylin analog; Known history of Type 1 diabetes mellitus.